• HyperScribe T7 High Yield RNA Synthesis Kit Plus: Evidence &

  2026-06-26

  The HyperScribe T7 High Yield RNA Synthesis Kit Plus enables rapid, high-yield in vitro transcription of RNA using T7 polymerase. This T7 RNA polymerase in vitro transcription kit supports synthesis of capped, labeled, or biotinylated RNA, with yields up to 180 μg per 20 μL reaction. Its validated performance underpins translational research, including RNA vaccine synthesis and mRNA rescue workflows.

• 4-Hydroxytamoxifen: Technical Guide for DMSO-Based Research

  2026-06-26

  4-Hydroxytamoxifen is a potent estrogen receptor modulator optimized for DMSO-soluble workflows in breast cancer, prostate cancer, and cardiac myocyte studies. It should not be used in ethanol- or water-based protocols, and requires precise handling and storage to maintain experimental reproducibility.

• Polygodial: TRPA1 Channel Activator for Sensory Ion Channel

  2026-06-25

  Polygodial is a validated TRPA1 channel activator that enables precise, reproducible modulation of sensory ion channels in epithelial and neuronal models. This article details optimized experimental workflows, troubleshooting insights, and practical innovations for membrane transporter signaling research, leveraging the latest published findings and the reliability of APExBIO’s Polygodial.

• Remdesivir (GS-5734) in Antiviral Research: Translational Im

  2026-06-25

  Explore how Remdesivir (GS-5734) advances antiviral research with unprecedented translational impact, integrating evidence from recent studies and practical workflow considerations. This deep-dive highlights unique assay decisions and comparative insights for coronavirus and Ebola virus research.

• Refining In Vitro Drug Response Assessment in Cancer Researc

  2026-06-24

  Schwartz's dissertation introduces a nuanced methodology for in vitro evaluation of anti-cancer drug responses, distinguishing between proliferative arrest and cell death. This approach improves the interpretation of compounds like Belinostat (PXD101) in epigenetic cancer therapy models, with broad implications for experimental reproducibility and translational relevance.

• Anagliptin (SK-0403): Mechanistic Depth for Translational Va

  2026-06-23

  Explore the advanced mechanistic underpinnings and translational opportunities of Anagliptin (SK-0403), a potent DPP-4 inhibitor, in vascular and glycemic research. This article integrates new insights on Kv channel and SERCA pump modulation, highlighting their relevance for diabetes and cardiovascular models. Strategic guidance is provided for researchers aiming to design precision assays and bridge metabolic and vascular endpoints.

• Elevating p16-Targeted Cancer Research with HyperScript RT S

  2026-06-23

  This thought-leadership article explores the mechanistic and strategic advances in gene expression analysis for p16-targeted therapies, highlighting the role of HyperScript™ RT SuperMix for qPCR in enabling robust, reproducible cDNA synthesis from challenging RNA templates. By integrating recent breakthroughs in antibody fragment-drug conjugates (AFDCs) with practical guidance for translational researchers, we delineate how optimized reverse transcription technologies accelerate biomarker discovery and therapeutic development in oncology.

• Ibrexafungerp and Caspofungin: Advances Against Drug-Resista

  2026-06-22

  Wiederhold et al. demonstrate that ibrexafungerp, a novel triterpenoid antifungal, maintains potent in vitro and in vivo efficacy against fluconazole-resistant Candida auris, even when therapy is delayed. Their findings reinforce the crucial role of β-(1,3)-D-glucan biosynthesis inhibition and provide comparative evidence with caspofungin, informing future antifungal research and experimental protocols.

• Anlotinib Hydrochloride: Optimizing Anti-Angiogenic Assays i

  2026-06-22

  This article guides biomedical researchers through practical challenges in angiogenesis and cell-based assays, illustrating how Anlotinib hydrochloride (SKU C8688) from APExBIO delivers robust, reproducible inhibition of VEGFR2, PDGFRβ, and FGFR1. Scenario-driven Q&A blocks offer actionable, data-backed insights for experimental design, protocol optimization, and vendor selection—grounding best practices in validated pharmacological and workflow evidence.

• Pexmetinib (ARRY-614): Optimizing Cytokine Inhibition Assays

  2026-06-21

  Pexmetinib (ARRY-614) streamlines cytokine inhibition workflows as a dual p38 MAPK and Tie2 inhibitor, delivering high specificity and reproducibility in inflammatory and myelodysplastic syndromes research. This guide details advanced use-cases, protocol enhancements, and troubleshooting strategies that maximize assay performance.

• Charge-Reversed Exosomes Enable Cartilage-Targeted mRNA Deli

  2026-06-20

  Zhang et al. present a non-viral gene delivery platform using charge-reversed exosomes to transport mRNA efficiently into dense cartilage tissue for osteoarthritis therapy. Their approach overcomes longstanding barriers in intra-cartilage delivery, demonstrating robust mRNA penetration and expression in deep chondrocyte layers, with strong translational potential for targeted gene therapies.

• Angiotensin II (A1042): Technical Guidance for Vascular Mode

  2026-06-19

  Angiotensin II (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe) is a validated peptide tool for inducing vasoconstriction, hypertension, and vascular remodeling in experimental research. This product is best suited for cell-based and animal models requiring precise control of vascular responses but is not intended for diagnostic or clinical use.

• Dual Glutamate Receptor Blockade Mitigates Soman-Induced Neu

  2026-06-19

  This study introduces a dual-targeting approach with IEM-1925 for blocking both AMPA and NMDA glutamate receptors, demonstrating robust protection against soman-induced status epilepticus and neurodegeneration in rats. The findings highlight significant advantages over standard therapies and underscore the translational potential of selective AMPA receptor blockers in acute neurotoxicity research.

• Network Pharmacology Identifies Apigenin for Alzheimer’s The

  2026-06-18

  A recent study employs a network medicine framework to systematically identify flavonoid candidates for Alzheimer’s disease (AD) therapy, highlighting Apigenin (5,7-dihydroxy-2-(4-hydroxyphenyl)chromen-4-one) as a leading neuroprotective agent. Experimental validation demonstrates that Apigenin modulates apoptosis, neuroinflammation, and key signaling pathways, providing actionable targets for translational research.

• Ultra Fast LC–MS/MS for Cefazedone & Etimicin: Pharmacokinet

  2026-06-18

  This study introduces an ultra fast liquid chromatography–tandem mass spectrometry (UFLC–MS/MS) method for the simultaneous quantification of cefazedone and etimicin in beagle dog plasma. The validated protocol enabled the first detailed pharmacokinetic comparison between combined and single-agent administration, revealing no significant pharmacokinetic interactions and supporting rational combination therapy.

461 records 14/31 page Previous Next First page 上5页 1112131415 下5页 Last page